EVENTS | VIEW CALENDAR
Agilent and BioTek join forces
SANTA CLARA Calif. & WINOOSKI Vt.—Agilent Technologies Inc. and BioTek Instruments Inc. in early April announced a new, integrated solution that combines cellular metabolic analysis and imaging technologies. The optimized solution integrates the Agilent’s XFe96/XFe24 Analyzers with the BioTek Cytation 1 Cell Imaging Multi-Mode Reader. This solution creates a standardized approach for comparing XF data sets, improving assay workflow, embedding images into WAVE software, and applying normalization values to XF measurements.
“The collaboration between Agilent and BioTek was a natural extension of our shared goal to advance scientific discovery through technological innovation,” said Gary Barush, global director of marketing and sales at BioTek. “Agilent’s automated XFe Analyzers, combined with BioTek’s Cytation 1 Cell Imaging Multi-Mode Reader, creates a distinct opportunity for cell biology researchers to fully normalize and analyze samples to answer challenging questions regarding cellular metabolism.”
“Agilent customers requested an optimized method for verifying assay results, and enabling more meaningful data comparisons provided by our data-rich assays,” said Dr. David Ferrick, senior director of Agilent’s Cell Analysis Division. “This integrated solution gives our customers the ability to compare XF data on a well-to-well, plate-to-plate, and experiment-to-experiment basis.”
Now researchers can toggle between XF data, brightfield images and fluorescence images in a unified software experience—referencing the images while analyzing XF data provides evidence and guidance on how to limit variability and improve the reproducibility of their XF assays. Applying a cell count based normalization value ultimately makes interpreting XF data and finding relationships amongst the data easier, the companies say.